NCT00002866View on ClinicalTrials.gov

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 12, 1996

Primary Completion Date

July 19, 2005

Study Completion Date

December 21, 2009

Conditions
Breast CancerNeutropenia
Interventions
BIOLOGICAL

filgrastim

DRUG

docetaxel

DRUG

epirubicin hydrochloride

Trial Locations (6)

E2L 4L2

Saint John Regional Hospital, Saint John

M4N 3M5

Toronto Sunnybrook Regional Cancer Centre, Toronto

M5G 1X5

Mount Sinai Hospital - Toronto, Toronto

M5G 2C4

Toronto General Hospital, Toronto

M5S 1B6

Women's College Campus, Sunnybrook and Women's College Health Science Center, Toronto

H2W 1T8

Hotel Dieu de Montreal, Montreal

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK